Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience-Reference-Cited by-同舟云学术

Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience

Published:2017-01-20 Issue:6 Volume:24 Page:464-471
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Muñoz-Gómez R.¹,Rincón D.²,Ahumada A.²,Hernández E.³,Devesa M. J.⁴,Izquierdo S.⁴,Ortiz M.⁵,Hernández-Albujar A.⁶,Fernández-Rodríguez C.⁷,Calvo M.⁸,González R.⁹,Lozano M.¹⁰,Castellano G.¹,Fernández-Vázquez I.¹

Affiliation:

1. Department of Gastroenterology; Hospital Universitario 12 de Octubre; Madrid Spain

2. Unit of Hepatology; Hospital Universitario Gregorio Marañón; CIBERehd; Madrid Spain

3. Department of Nephrology; Hospital Universitario 12 de Octubre; Madrid Spain

4. Department of Gastroenterology; Hospital Universitario Clínico San Carlos; Madrid Spain

5. Department of Gastroenterology; Hospital Universitario Infanta Cristina; Madrid Spain

6. Department of Gastroenterology; Hospital General Universitario de Ciudad Real; Ciudad Real Spain

7. Department of Gastroenterology; Hospital Universitario Fundación Alcorcón; Madrid Spain

8. Department of Gastroenterology; Complejo Asistencial de Segovia; Segovia Spain

9. Department of Gastroenterology; Hospital Universitario del Sureste; Madrid Spain

10. Department of Gastroenterology; Hospital Universitario Infanta Leonor; Madrid Spain

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12664/fullpdf

Reference28 articles.

1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

2. Hepatitis C infection is very rarely treated among hemodialysis patients;Goodkin;Am J Nephrol,2013

3. Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy;Morales;Contrib Nephrol,2012

4. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis;Lee;PLoS ONE,2014

5. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies;Fabrizi;J Viral Hepat,2014

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Treating HCV Genotypes 1 and 4 in Patients with Advanced Chronic Kidney Disease;Journal of Pharmacy and Bioallied Sciences;2024-07

2. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis;Frontiers in Public Health;2023-09-29

3. A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD;Kidney International Reports;2023-02

4. KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease;Kidney International;2022-12

5. An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease;Pathogens;2021-10-26